Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
9th February 2021 | Capital Management, L.P. Ra | 2,848,596 | Open or private purchase | $18.00 | $51,274,728.00 |
9th February 2021 | Capital Management, L.P. Ra | 1,664,549 | Conversion of derivative | $0.00 | |
9th February 2021 | Capital Management, L.P. Ra | 280,330 | Conversion of derivative | $0.00 | |
9th February 2021 | Capital Management, L.P. Ra | 130,970 | Open or private purchase | $18.00 | $2,357,460.00 |
9th February 2021 | Capital Management, L.P. Ra | 3,784,120 | Conversion of derivative | $0.00 | |
9th February 2021 | Capital Management, L.P. Ra | 1,414,026 | Conversion of derivative | $0.00 | |
4th February 2021 | Capital Management, L.P. Ra | 11,651,597 | Conversion of derivative | $0.00 | |
6th January 2021 | Frank Neumann | 150,000 | Grant/award etc. | $0.00 | |
18th December 2020 | Dan Paterson | 135,851 | Grant/award etc. | $0.00 | |
18th December 2020 | Brian M Stuglik | 203,776 | Grant/award etc. | $0.00 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 7/10.
Verastem, Inc. is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K)
27th December 2020